medmix Drug Delivery (Haselmeier): PiccoJect wins Good Design Award

22 December 2022

medmix, global leader in high-precision delivery devices, won the prestigious Good Design™ Award 2022 in the Medical category for PiccoJect™, the autoinjector from medmix Drug Delivery (Haselmeier™). PiccoJect™ is a disposable two-step autoinjector designed for subcutaneous injection.

With a focus on patient centric design and a commitment to sustainability, PiccoJect is composed of only eight parts and features an ergonomic shape and a large wrap-around drug window. Haselmeier is offering PiccoJect as a full-service platform including combination product development, design verification, final assembly, secondary packaging, labeling and serialization. This is the second time that Haselmeier – a medmix brand, wins the Good Design award after the D-Flex™ Ecosystem won the award in 2020.

PiccoJect by medmix Drug Delivery (Haselmeier)

Chris Muenzer, Vice President of Innovation and Development of Haselmeier, said: “We are proud of our PiccoJect winning the well-recognized Good Design award. This award confirms our ambition for PiccoJect to meet the needs both of our pharmaceutical customers and of their patients. With this in mind, we focused on three key aspects during the development of PiccoJect: consistent and repeatable performance, patient-centric design and a commitment to sustainability.”

PiccoJect is specifically designed to have a significantly reduced part count of only eight components. This improved device design reduces manufacturing and scale up challenges that can impact performance. The autoinjector platform is fully customizable based on customer needs including support for different fill volumes and drug viscosities, color options for the cap and an adjustable size of the drug window. “In addition, the design of PiccoJect includes a number of connectivity options that are either integrated or provided as an add-on module, without modifying the core mechanism or compromising handling”, Chris added.

PiccoJect is designed for patients and non-professional care givers to administer an injection in a home setting and can also be used by nurses and other health care professionals in the clinic. The device is applicable for the use in any drug product that is packaged in a prefilled syringe. This includes novel biologics for indications such as arthritis, asthma, cancer, cardiovascular disease, diabetes, autoimmune diseases, genetic disorders, and some viral diseases such as hepatitis. In addition, the use in biosimilars of existing drugs like adalimumab and etanercept is also a focus.

Good Design Award: The Chicago Athenaeum continues the organisation of the program to create an awareness about contemporary design and to honor both products and industry leaders in design and manufacturing that have chartered new directions for innovation and pushed the envelope for competitive products in the world marketplace. Good Design was founded in Chicago in 1950 by Edgar Kaufmann, Jr., Eero Saarinen, and Charles and Ray Eames. Mort Goldsholl also created the iconic Good Design logo in 1950.

Facts and figures about PiccoJect:

  • Low part count of only eight components
  • Patient-centric design with an ergonomic shape and a large wrap-around drug window
  • A full-service platform with consistent and repeatable performance
  • Disposable two-step autoinjector for subcutaneous injection
  • Developed for a standard 1 ml long or 2.25 ml pre-filled glass or plastic syringes
  • Fill volumes from 0.2 ml to 2.0 ml
  • Viscosity up to 20 cP

medmix PiccoJect is easy to customize

About medmix

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 13 production sites worldwide together with our highly motivated and experienced team of nearly 2’000 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX).


Media Relations: Peter Trampert, Senior Communications Manager

Investor Relations: Sheel Gill, Head of Investor Relations 

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.